Zydus Lifesciences Limited

Form 483 issued May 5, 2026 · Ahmedabad, India

Inspection
Apr 27 – May 5, 2026
Observations
2
Pages
7
FEI number
3012977526

In short: On May 5, 2026, FDA issued a Form 483 with 2 observations to Zydus Lifesciences Limited in Ahmedabad, India (FEI 3012977526) after an inspection that ran Apr 27 – May 5, 2026. The investigators were Brandy N. Lepage and Jessica S. Estriplet. Most observations concern quality system and production; the most-cited regulation is 21 CFR 211.192 (production record review).

At a glance

Quality system and production account for 2 of 2 observations.

Quality system1
Production1

Most cited: 21 CFR 211.192 (1×) · 211.113(b) (1×)

What FDA observed

Preview: the opening words of each observation
  1. 01

    There is a failure to thoroughly review any unexplained discrepancy whether or not the batch…

  2. 02

    Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Zydus Lifesciences Limited?

FDA listed 2 observations on this Form 483, mostly about quality system and production. The most-cited regulation is 21 CFR 211.192 (production record review). The opening words of each observation are shown on this page.

Who inspected Zydus Lifesciences Limited?

Brandy N. Lepage and Jessica S. Estriplet are named on this Form 483, for the inspection of Apr 27 – May 5, 2026. Each investigator has a profile showing what they cite most.

When was Zydus Lifesciences Limited inspected by FDA?

The inspection ran Apr 27 – May 5, 2026, and the Form 483 is dated May 5, 2026.

How do I get the full Form 483 for Zydus Lifesciences Limited?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free